Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults, \>/=18 years of age~* metastatic melanoma, stage IIIC or IV (AJCC)~* treatment-naïve (no prior systemic anticancer therapy)~* positive for BRAF V600E mutation~* measurable disease by RECIST criteria~* negative pregnancy test and, for fertile men and women, effective contraception during treatment and for 6 months after completion~Exclusion Criteria:~* active central nervous system metastases~* history of carcinomatous meningitis~* severe cardiovascular disease within 6 months prior to study drug administration~* previous malignancy within 5 years prior to study, except for basal or squamous cell carcinoma of the skin, melanoma in-situ, or carcinoma in-situ of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vemurafenib (Type: EXPERIMENTAL): None
- Dacarbazine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).